AG
RARX

Aperio Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Aperio Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-413
Closed -$12K – 2979
2019
Q2 		$12K Buy
+413
New +$9.46K ﹤0.01% 2769

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Aperio Group's RARX Position: Q3 2019 in Review

Aperio Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2019, closing a stake of 413 shares — an estimated $12K sold.

Aperio Group first reported a position in RARX in Q2 2019 and held it in 1 quarter. The position peaked at $12K in Q2 2019. 119 funds tracked by Wall St. Rank hold RARX as of Q3 2019.

  • Aperio Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 413 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $12K.
  • Aperio Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Aperio Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12K in Q2 2019.
  • 119 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.